中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 9
Sep.  2014
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2014  >  30(9): 913-916

Clinical effects of comprehensive treatment and liver transplantation for hepatocellular carcinoma exceeding Milan criteria: a comparative study

DOI: 10.3969/j.issn.1001-5256.2014.09.019

  • Department of Hepatobiliary Surgery, Fuzhou General Hospital of Nanjing Military Region

Research funding:

 

  • Received Date: 2014-01-21
  • Published Date: 2014-09-20
    Abstract

  • Objective To analyze and compare the clinical effects of comprehensive treatment and liver transplantation for hepatocellular carcinomas ( HCC) exceeding Milan criteria. Methods A retrospective analysis was performed on the clinical data of 157 patients with HCC ( exceeding Milan criteria) who received comprehensive treatment ( 99 patients, including 48 cases meeting Shanghai criteria) and liver transplantation ( 58 patients, including 26 cases meeting Shanghai criteria) in our hospital from January 2006 to January 2010. The median survival times and 1-, 2-, and 3- year survival rates were calculated by the Kaplan- Meier method, and the log- rank test was used for survival difference analysis. Results For all patients, the median survival times of the comprehensive treatment group and liver transplantation group were 18. 00 ± 1. 15 and 23. 40 ± 4. 44 months, respectively, and their 3- year survival rates were ( 18. 2 ± 3. 9) % and ( 39. 7 ±6.4) %, respectively; the survival was significantly improved by the treatment of liver transplantation ( P =0.009) . For patients meeting Shanghai criteria, the median survival times of the comprehensive treatment group and liver transplantation group were 20. 00 ± 1. 17 and 36. 00 ± 0. 00 months, respectively, and their 3- year survival rates were ( 25. 0 ± 6. 3) % and ( 57. 7 ± 9. 7) %, respectively; there was significant survival difference between the two groups ( P = 0. 008) . For patients exceeding Shanghai criteria, the median survival times of the comprehensive treatment group and liver transplantation group were 16. 00 ± 1. 78 and 16. 00 ± 1. 69 months, respectively, and their 3- year survival rates were ( 11. 8 ± 4. 5) % and ( 25. 0 ± 7. 7) %, respectively; there was no significant survival difference between the two groups ( P = 0. 221) . Conclusion Compared with comprehensive treatment, liver transplantation leads to a significant higher long- term survival rate in HCC patients exceeding Milan criteria but meeting Shanghai criteria. However, the two therapies cause no significant survival difference in HCC patients exceeding Shanghai criteria.

     

    • FullText(HTML)
    • References(13)
  • [1]Ministry of Health of the People's Republic of China.Diagnosis, management, and treatment of hepatocellular carcinoma (V2011) [J].J Clin Hepatol, 2011, 27 (11) :1141-1159. (in Chinese) 中华人民共和国卫生部.原发性肝癌诊疗规范 (2011年版) [J].临床肝胆病杂志, 2011, 27 (11) :1141-1159.
    [2]SHEN F, XIA Y.A superficial view on clinical studies of comprehensive surgical management of liver cancer[J].J Surg Concepts Pract, 2010, 15 (3) :205-207. (in Chinese) 沈锋, 夏勇.肝癌外科综合治疗的临床研究之浅见[J].外科理论与实践, 2010, 15 (3) :205-207.
    [3] JEMAL A, BRAY F, CENTER MM, et al.Global cancer statistics[J].CA Cancer J Clin, 2011, 61 (2) :69-90.
    [4] FAN J, YANF GS, FU ZR, et al.Liver transplantation outcomes in1, 078 hepatocellular carcinoma patients:a multicenter experience in Shanghai, China[J].J Cancer Res Clin Oncol, 2009, 135 (10) :1403-1412.
    [5] McGLYNN KA, LONDON WT.The global epidemioloiry of hepatocellular carcinoma:present and future[J].Clin Liver Dis, 2011, 15 (2) :223-243.
    [6]National Comprehensive Cancer Network.Hepatobiliary Cancer Network[J].Hepatobiliary Cancers.www.org 2010, Vol.V.2.
    [7]POPESCU I, IONESCU M, CIUREA S, et al.Current treatment of hepatocellular carcinoma.Analysis of a series of 123 cases over a 5-year period[J].Chirurgia (Bucur) , 2005, 100 (4) :321-331.
    [8] FAN J, ZHOU J, XU Y.Re-evaluation of“Shanghai Criteria”:indication of liver transplantation for hepatocelluar carcinoma[J].Chin J Organ Transplant, 2013, 34 (9) :521-523. (in Chinese) 樊嘉, 周俭, 徐泱.“上海标准”在肝癌肝移植适应症中应用13年的回顾分析[J].中华器官移植杂志, 2013, 34 (9) :521-523.
    [9]BAI W, HAN GH.Comprehensive intervention treatment for hepatocellular[J].J Clin Hepatol, 2013, 29 (1) :36-37. (in Chinese) 白苇, 韩国宏.肝细胞癌的综合介入治疗[J].临床肝胆病杂志, 2013, 29 (1) :36-37.
    [10] CHEN MS, LI JQ, ZHENG Y, et al.A prospective randomized trial comparing pcrcutancous local ablative therapy and partial hepatectomy for small hepatoccllular carcinoma[J].Ann Surg, 2006, 243 (3) :321-328.
    [11]LEE IJ, SEONG J.The optimal selection of radiotherapy treatment for hepatoccllular carcinoma[J].Cut Liver, 2012, 6 (2) :139-148.
    [12]KIM JY, CHUNH SM, CHOI BO, et al.Hepatoccllular carcinoma with portal vein tumor thrombosis:improved treatment outcomes with extenal beam radiation therapy[J].Hepatol Res, 2011, 41 (9) :813-824.
    [13] WU MC, ZHOU WP, PAN ZY.New challenges for surgical treatment of hepatocellar carcinoma[J].Infect Dis Info, 2012, 25 (5) :257-263. (in Chinese) 吴孟超, 周伟平, 潘泽亚.肝癌外科治疗新挑战[J].传染病信息, 2012, 25 (5) :257-263.引证本文:LIU JY, CAI QC, JIANG Y.Clinical effects of comprehensive treatment and liver transplantation for hepatocellular carcinoma exceeding Milan criteria:a comparative study[J].J Clin Hepatol, 2014, 30 (10) :913-916. (in Chinese) 刘建勇, 蔡秋程, 江艺.超出米兰标准的肝癌患者综合治疗和肝移植的疗效比较[J].临床肝胆病杂志, 2014, 30 (10) :913-916.
    • Relative Articles

  • Relative Articles

    [1]Huaqiang ZHANG, Lixin LIU, Xiaohong GUO. Association of nonalcoholic fatty liver disease with the risk of colorectal adenoma and colorectal cancer: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(7): 1619-1625. doi: 10.3969/j.issn.1001-5256.2021.07.028
    [2]Qiaohong LIU, Yu ZHAO, Yiyang HU. Effect of diet on enterotype-related gut microbiota in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(4): 939-942. doi: 10.3969/j.issn.1001-5256.2021.04.046
    [3]Juan PENG, Liangping LI. Mechanism of action of estrogen and its receptor in the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(2): 467-470. doi: 10.3969/j.issn.1001-5256.2021.02.046
    [4]Jinhong TANG, Long WANG. Research advances in the association between nonalcoholic fatty liver disease and colorectal adenomatous polyps[J]. Journal of Clinical Hepatology, 2021, 37(11): 2672-2675. doi: 10.3969/j.issn.1001-5256.2021.11.040
    [5]Yalan LEI, Jian BI, Jingwei MAO. Impact of nonalcoholic fatty liver disease on intestinal immune cells[J]. Journal of Clinical Hepatology, 2021, 37(11): 2667-2671. doi: 10.3969/j.issn.1001-5256.2021.11.039
    [6]Shenglan ZENG, Rongzhen ZHANG, Na WANG, Tingshuai WANG, Liting TAN, Dewen MAO. Effect of diet-gut microbiota axis on nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(11): 2676-2679. doi: 10.3969/j.issn.1001-5256.2021.11.041
    [7]Chenlu ZHAO, Wenxia ZHAO. Influence of estrogen deficiency on metabolic associated fatty liver disease in postmenopausal women[J]. Journal of Clinical Hepatology, 2021, 37(7): 1708-1712. doi: 10.3969/j.issn.1001-5256.2021.07.049
    [8]Tian TIAN, Wenwei HU, Xue LI, Jie WU, Dan ZHANG, Changzheng LI. Association between thyroxine level and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(10): 2357-2363. doi: 10.3969/j.issn.1001-5256.2021.10.020
    [9]Xiangqian HUANG, Xiaomeng YAN, Mingda ZHANG, Jing WU, Jianhong CHEN. Association between nonalcoholic fatty liver disease and colorectal neoplasms[J]. Journal of Clinical Hepatology, 2021, 37(12): 2947-2950. doi: 10.3969/j.issn.1001-5256.2021.12.045
    [10]SUN MengYuan, XIANG XiaoXing. Role of gut microbiota and bile acid pathway in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(12): 2831-2834. doi: 10.3969/j.issn.1001-5256.2020.12.040
    [11]Li HongShan, Hu YiYang. Gut microecology: An important target of traditional Chinese medicine in the treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(1): 14-18. doi: 10.3969/j.issn.1001-5256.2020.01.002
    [12]Hui DengCheng, Sun MingYu. Association between nonalcoholic fatty liver disease and gut microbiota based on the theory of gut-liver axis[J]. Journal of Clinical Hepatology, 2020, 36(7): 1627-1630. doi: 10.3969/j.issn.1001-5256.2020.07.039
    [13]Zhang Dan, Zhou Bo, Deng Yi, Wen Yu, Lu: JunYan, Wang JinXiang, Geng ZuoTao, Luo SuFeng, Ying YunYan, Wen DaiYan, Shi ChunJing, Pu GuangYu, Jiang Xin, Ma LanQing. Effect of fenofibrate on the diversity of intestinal flora in a mouse model of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(4): 829-834. doi: 10.3969/j.issn.1001-5256.2020.04.024
    [14]Chuan LiXue, Chang Jiang, Zhao JinHan, Li LuoHua, Yang XuYao, Yu Di. Association between nonalcoholic fatty liver disease and colorectal adenomatous polyps[J]. Journal of Clinical Hepatology, 2020, 36(6): 1299-1303. doi: 10.3969/j.issn.1001-5256.2020.06.022
    [15]Feng Gong, He Na, Mi Man, Li XuePing, Liu ManLing, Fan LiPing, Niu ChunYan. Risk factors for the coexistence of inflammatory bowel disease and nonalcoholic fatty liver disease: A Meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(4): 835-839. doi: 10.3969/j.issn.1001-5256.2019.04.025
    [16]Liu SiFu, Xie ZhengYuan. Association between nonalcoholic fatty liver disease and colorectal tumors[J]. Journal of Clinical Hepatology, 2019, 35(9): 2091-2094. doi: 10.3969/j.issn.1001-5256.2019.09.046
    [17]Zhang XiaXia, Xu HongTuan, Xu YouQing. The natural history and clinical features of nonalcoholic fatty liver disease-related cirrhosis[J]. Journal of Clinical Hepatology, 2018, 34(1): 24-26. doi: 10.3969/j.issn.1001-5256.2018.01.004
    [18]Liu JiaQi, Zhou ShaoMing. Research advances in intestinal flora in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2453-2456. doi: 10.3969/j.issn.1001-5256.2017.12.045
    [19]Lu Xu, Han Tao, Tian Yao, Lu BoWei, Zhang Qian. Research progress in roles of gut microbiota and bile acid metabolism in development and progression of NAFLD[J]. Journal of Clinical Hepatology, 2014, 30(11): 1225-1228. doi: 10.3969/j.issn.1001-5256.2014.11.034
    [20]Zhu Peng, Xu Zong, Wang YuMing. World Gastroenterology Organisation global guidelines：nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2014, 30(9): 842-845. doi: 10.3969/j.issn.1001-5256.2014.09.002
    • Supplements(0)
    • Cited By
  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-032025-040102030
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 15.4 %FULLTEXT: 15.4 %META: 78.3 %META: 78.3 %PDF: 6.3 %PDF: 6.3 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 8.3 %其他: 8.3 %其他: 1.0 %其他: 1.0 %Australia: 0.2 %Australia: 0.2 %China: 1.0 %China: 1.0 %Egypt: 0.3 %Egypt: 0.3 %India: 0.8 %India: 0.8 %Iraq: 0.3 %Iraq: 0.3 %Russian Federation: 0.2 %Russian Federation: 0.2 %United Kingdom: 0.1 %United Kingdom: 0.1 %United States: 0.2 %United States: 0.2 %[]: 1.0 %[]: 1.0 %上海: 1.3 %上海: 1.3 %中卫: 1.0 %中卫: 1.0 %临汾: 0.1 %临汾: 0.1 %临沧: 0.1 %临沧: 0.1 %丽水: 0.1 %丽水: 0.1 %乌鲁木齐: 0.1 %乌鲁木齐: 0.1 %伊犁: 0.1 %伊犁: 0.1 %佛山: 0.1 %佛山: 0.1 %凉山彝族自治州: 0.1 %凉山彝族自治州: 0.1 %北京: 8.1 %北京: 8.1 %北阿坎德: 0.3 %北阿坎德: 0.3 %南京: 0.4 %南京: 0.4 %南充: 0.1 %南充: 0.1 %南宁: 0.4 %南宁: 0.4 %南昌: 0.2 %南昌: 0.2 %南阳: 0.1 %南阳: 0.1 %卡纳塔克: 0.2 %卡纳塔克: 0.2 %台州: 0.7 %台州: 0.7 %吉林: 1.6 %吉林: 1.6 %呼和浩特: 0.2 %呼和浩特: 0.2 %唐山: 0.8 %唐山: 0.8 %嘉兴: 0.1 %嘉兴: 0.1 %四平: 0.1 %四平: 0.1 %多伦多: 0.1 %多伦多: 0.1 %大连: 0.1 %大连: 0.1 %天津: 1.2 %天津: 1.2 %常德: 0.1 %常德: 0.1 %广州: 0.9 %广州: 0.9 %延边: 0.2 %延边: 0.2 %弗吉尼亚州: 0.1 %弗吉尼亚州: 0.1 %张家口: 1.5 %张家口: 1.5 %徐州: 0.1 %徐州: 0.1 %成都: 0.5 %成都: 0.5 %新乡: 0.1 %新乡: 0.1 %新余: 0.1 %新余: 0.1 %昆明: 1.3 %昆明: 1.3 %晋城: 0.1 %晋城: 0.1 %曼谷: 0.1 %曼谷: 0.1 %朝阳: 0.1 %朝阳: 0.1 %杭州: 0.3 %杭州: 0.3 %松原: 0.1 %松原: 0.1 %武汉: 1.1 %武汉: 1.1 %河池: 0.1 %河池: 0.1 %泰州: 0.1 %泰州: 0.1 %济南: 0.3 %济南: 0.3 %海得拉巴: 0.4 %海得拉巴: 0.4 %淄博: 0.2 %淄博: 0.2 %淮北: 0.1 %淮北: 0.1 %淮安: 0.1 %淮安: 0.1 %深圳: 0.5 %深圳: 0.5 %湖州: 0.1 %湖州: 0.1 %湘潭: 0.1 %湘潭: 0.1 %潍坊: 0.1 %潍坊: 0.1 %珠海: 0.1 %珠海: 0.1 %眉山: 0.1 %眉山: 0.1 %石家庄: 0.2 %石家庄: 0.2 %秦皇岛: 0.1 %秦皇岛: 0.1 %聊城: 0.1 %聊城: 0.1 %芒廷维尤: 37.1 %芒廷维尤: 37.1 %芝加哥: 0.2 %芝加哥: 0.2 %苏州: 0.2 %苏州: 0.2 %莫斯科: 2.4 %莫斯科: 2.4 %莱芜: 0.1 %莱芜: 0.1 %衢州: 0.1 %衢州: 0.1 %襄阳: 0.1 %襄阳: 0.1 %西宁: 15.0 %西宁: 15.0 %贵阳: 0.4 %贵阳: 0.4 %辽阳: 0.1 %辽阳: 0.1 %运城: 1.8 %运城: 1.8 %连云港: 0.1 %连云港: 0.1 %邯郸: 0.1 %邯郸: 0.1 %重庆: 0.3 %重庆: 0.3 %银川: 0.2 %银川: 0.2 %锦州: 0.1 %锦州: 0.1 %长春: 1.4 %长春: 1.4 %长沙: 0.1 %长沙: 0.1 %鞍山: 0.1 %鞍山: 0.1 %香港: 0.1 %香港: 0.1 %鹤壁: 0.1 %鹤壁: 0.1 %黄冈: 0.1 %黄冈: 0.1 %黔南: 0.1 %黔南: 0.1 %其他其他AustraliaChinaEgyptIndiaIraqRussian FederationUnited KingdomUnited States[]上海中卫临汾临沧丽水乌鲁木齐伊犁佛山凉山彝族自治州北京北阿坎德南京南充南宁南昌南阳卡纳塔克台州吉林呼和浩特唐山嘉兴四平多伦多大连天津常德广州延边弗吉尼亚州张家口徐州成都新乡新余昆明晋城曼谷朝阳杭州松原武汉河池泰州济南海得拉巴淄博淮北淮安深圳湖州湘潭潍坊珠海眉山石家庄秦皇岛聊城芒廷维尤芝加哥苏州莫斯科莱芜衢州襄阳西宁贵阳辽阳运城连云港邯郸重庆银川锦州长春长沙鞍山香港鹤壁黄冈黔南

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (3274) PDF downloads(493) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2389]YesterdayPV[5285]TodayIP[1960]TodayPV[4323]Online[50]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return